Trial Profile
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 23 Aug 2021 Results (n=11) assessing development and exfoliation patterns of primary and permanent teeth in infants and children with HPP and the impact of ERT with asfotase alfa, published in the Bone.
- 18 Mar 2019 Pooled results from this and five other studies were presented at the 101st Annual Meeting of the Endocrine Society.
- 27 Feb 2019 Results evaluating efficacy and safety of asfotase alfa in patients with Hypophosphatasia published in the Journal of Clinical Endocrinology and Metabolism